CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication in vitro and in vivo.

ABSTRACT: The COVID-19 pandemic has claimed over 6.5 million lives worldwide and continues to have lasting impacts on the world's healthcare and economic systems. Several approved and emergency authorized therapeutics that inhibit early stages of the virus replication cycle have been developed however, effective late-stage therapeutical targets have yet to be identified. To that end, our lab identified that 2',3' cyclic-nucleotide 3'-phosphodiesterase (CNP) inhibits SARS-CoV-2 virion assembly. We show that CNP inhibits the generation of new SARS-CoV-2 virions, reducing intracellular titers without inhibiting viral structural protein translation. Additionally, we show that targeting of CNP to mitochondria is necessary for inhibition, blocking mitochondrial depolarization and implicating CNP's propose

SUBMITTER: Logue J 

PROVIDER: S-EPMC10766180 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature